Detalles de la búsqueda
1.
CD69 controls the uptake of L-tryptophan through LAT1-CD98 and AhR-dependent secretion of IL-22 in psoriasis.
Nat Immunol
; 17(8): 985-96, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27376471
2.
A Novel Circulating MicroRNA for the Detection of Acute Myocarditis.
N Engl J Med
; 384(21): 2014-2027, 2021 05 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-34042389
3.
Implementing well-being in the management of psoriasis: An expert recommendation.
J Eur Acad Dermatol Venereol
; 38(2): 302-310, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37822008
4.
KEAP1-NRF2 protein-protein interaction inhibitors: Design, pharmacological properties and therapeutic potential.
Med Res Rev
; 43(1): 237-287, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36086898
5.
Erratum: CD69 controls the uptake of L-tryptophan through LAT1-CD98 and AhR-dependent secretion of IL-22 in psoriasis.
Nat Immunol
; 17(10): 1235, 2016 09 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-27648548
6.
PsoBarrier EU study: a Multicentre, Cross-sectional Survey Investigating the Quality of Psoriasis Care in Four European Countries.
Acta Derm Venereol
; 103: adv6532, 2023 Aug 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37649411
7.
Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
J Eur Acad Dermatol Venereol
; 37(12): 2517-2525, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37625815
8.
Expression of microRNA-21 and TIMP-3 in paradoxical psoriasiform reactions during treatment with antitumor necrosis factor agents.
J Cutan Pathol
; 49(2): 116-122, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34322902
9.
Cutaneous vascular calcification. Perieccrine calcification as a diagnostic key for calciphylaxis.
J Cutan Pathol
; 49(8): 683-691, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35357702
10.
Ustekinumab to guselkumab transitions: A series of 54 patients emulating the navigate trial in real life.
Dermatol Ther
; 35(10): e15757, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36190008
11.
Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting.
Dermatol Ther
; 35(8): e15653, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35731640
12.
Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients.
Dermatol Ther
; 35(12): e15929, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36223184
13.
DNA Copy Number Variation Associated with Anti-tumour Necrosis Factor Drug Response and Paradoxical Psoriasiform Reactions in Patients with Moderate-to-severe Psoriasis.
Acta Derm Venereol
; 101(5): adv00448, 2021 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33846759
14.
Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort.
Acta Derm Venereol
; 101(1): adv00354, 2021 01 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33269405
15.
Targeting L-type amino acid transporter 1 in innate and adaptive T cells efficiently controls skin inflammation.
J Allergy Clin Immunol
; 145(1): 199-214.e11, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31605740
16.
Utility of circulating serum miRNA profiles to evaluate the potential risk and severity of immune-mediated inflammatory disorders.
J Autoimmun
; 111: 102472, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32381457
17.
Genome-wide association analysis of psoriasis patients treated with anti-TNF drugs.
Exp Dermatol
; 29(12): 1225-1232, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33058233
18.
Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry.
J Am Acad Dermatol
; 83(1): 139-150, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32213306
19.
Reduced doses of biological therapies in psoriasis may increase efficiency without decreasing drug survival.
Dermatol Ther
; 33(6): e14134, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32761730
20.
Cutaneous side effects in a cohort of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: General description and further characterization, correlation with photoexposition and study of hypopigmentation as treatment's prognostic factor.
Dermatol Ther
; 33(6): e14428, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33073453